DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Zypitamag is a drug marketed by Medicure and is included in one NDA. There is one patent protecting this drug.
This drug has two patent family members in two countries.
The generic ingredient in ZYPITAMAG is pitavastatin magnesium. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pitavastatin magnesium profile page.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 19, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Generic Entry Opportunity Date for ZYPITAMAG
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Medicure||ZYPITAMAG||pitavastatin magnesium||TABLET;ORAL||208379-001||Jul 14, 2017||DISCN||Yes||No||Start Trial||Start Trial||Y||Y||Start Trial|
|Medicure||ZYPITAMAG||pitavastatin magnesium||TABLET;ORAL||208379-002||Jul 14, 2017||RX||Yes||No||Start Trial||Start Trial||Y||Y||Start Trial|
|Medicure||ZYPITAMAG||pitavastatin magnesium||TABLET;ORAL||208379-003||Jul 14, 2017||RX||Yes||Yes||Start Trial||Start Trial||Y||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|